SCHEMBL17028624

SCHEMBL17028624

CC1(O)CCCc2cc(Br)ccc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.48
BACE1 P56817 2/20 0.41
APP P05067 1/20 0.41
PARP1 P09874 1/20 0.39
PNMT P11086 2/20 0.36
ASIC3 Q9UHC3 1/20 0.36
KDM1A O60341 4/20 0.36
CYP17A1 P05093 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP11B1 P15538 2/20 0.34
CYP11B2 P19099 2/20 0.34
SYK P43405 1/20 0.34
HSD17B3 P37058 2/20 0.33
TDP2 O95551 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18085630 0.89 KDM1A (0.41) PGRBACE1APPPARP1PNMT
SCHEMBL30721221 0.89 KDM1A (0.41) PGRBACE1APPPARP1PNMT
SCHEMBL17920089 0.88 BACE1 (0.49) PGRBACE1APPPARP1PNMT
SCHEMBL29577179 0.88 BACE1 (0.49) PGRBACE1APPPARP1PNMT
SCHEMBL2016698 0.82 BACE1 (0.43) BACE1APPPARP1PNMTASIC3
SCHEMBL17028703 0.77 BACE1 (0.40) PGRBACE1APPPARP1PNMT
SCHEMBL31650219 0.77 KDM1A (0.58) PGRPARP1KDM1ACYP3A4ADRA2A
SCHEMBL19764436 0.77 KDM1A (0.48) BACE1APPPNMTASIC3KDM1A
SCHEMBL5749365 0.77 KDM1A (0.58) PGRPARP1KDM1ACYP3A4ADRA2A
SCHEMBL30594684 0.77 KDM1A (0.50) BACE1APPPARP1PNMTASIC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107901-B1 COMPOUNDS FOR USE AS GPR120 AGONISTS PIRAMAL ENTPR LTD (IN) 2020-04-01 EP disclosed
US-10227360-B2 Compounds for use as GPR120 agonists Piramal Enterprises Limited (IN) 2019-03-12 US disclosed
EP-3107901-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2016-12-28 EP disclosed
US-20160347768-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2016-12-01 US disclosed
WO-2015125085-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227360-B2 Compounds for use as GPR120 agonists GPR119, GPR55, GPR180 PGR 1866/4885BACE1 1240/4885APP 606/4885
US-20160347768-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS GPR119, GPR55, GPR180 PGR 1866/4885BACE1 1240/4885APP 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.